TY  - JOUR
AU  - Saad, Fred
AU  - Small, Eric J
AU  - Feng, Felix Y
AU  - Graff, Julie N
AU  - Olmos, David
AU  - Hadaschik, Boris A
AU  - Oudard, Stéphane
AU  - Londhe, Anil
AU  - Bhaumik, Amitabha
AU  - Lopez-Gitlitz, Angela
AU  - Thomas, Shibu
AU  - Mundle, Suneel D
AU  - Chowdhury, Simon
AU  - Smith, Matthew R
PY  - 2021
DO  - 10.1016/j.eururo.2021.11.020
UR  - http://hdl.handle.net/10668/22224
T2  - European urology
AB  - Apalutamide plus androgen deprivation therapy (ADT) significantly improved metastasis-free survival (MFS), overall survival (OS), and time to prostate-specific antigen (PSA) progression in the placebo-controlled SPARTAN study of high-risk...
LA  - en
KW  - Androgen antagonists
KW  - Nonmetastatic castration-resistant prostate cancer
KW  - Prostate-specific antigen kinetics
KW  - Prostatic neoplasm
KW  - Androgen Antagonists
KW  - Androgens
KW  - Humans
KW  - Male
KW  - Prostate-Specific Antigen
KW  - Prostatic Neoplasms, Castration-Resistant
KW  - Thiohydantoins
TI  - Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN.
TY  - research article
VL  - 81
ER  -